Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals (KALV), exercised 33,800 stock options on May 27, 2026, and sold the shares for approximately $905,000. This transaction marks only his second open-market sale, reducing his direct holdings to 229,918 shares valued at about $6.16 million. Notably, Yea sold shares at $26.78 each even while a buyout offer of $27 per share from Chiesi Group is pending, expected to close in Q3 2026. KalVista’s lead drug, Ekterly, shows promising sales but the company recorded substantial losses recently.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/coverage/filings/2026/05/31/kalvista-s-kalv-chief-development-officer-sells-33-800-shares-for-usd905-000/
